Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 114 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Doumas, Michael  [Clear All Filters]
2018
Stavropoulos, K., Imprialos K. P., Athyros V. G., & Doumas M. (2018).  Renal resistive index for renovascular hypertension: In the quest of the Holy Grail.. J Clin Hypertens (Greenwich). 20(3), 589-591.
Doumas, M., Stavropoulos K., Imprialos K. P., Athyros V. G., & Karagiannis A. (2018).  Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. J Clin Hypertens (Greenwich). 20(4), 634-636.
Stavropoulos, K., Imprialos K. P., & Doumas M. (2018).  Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.. J Clin Hypertens (Greenwich). 20(1), 65-68.
Stavropoulos, K., Imprialos K. P., Stavropoulos N., Bouloukou S., Kerpiniotis G., Dimitriadis K., et al. (2018).  Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.. Cardiovasc Hematol Disord Drug Targets. 18(2), 120-126.
Imprialos, K. P., Stavropoulos K., & Doumas M. (2018).  Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs.. Cardiovasc Hematol Disord Drug Targets. 18(2), 83-85.
Stavropoulos, K., Imprialos K. P., Doumas M., Athyros V. G., & Karagiannis A. (2018).  Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?. J Hypertens. 36(3), 701.
Stavropoulos, K., Imprialos K., Doumas M., & Athyros V. G. (2018).  What is the role of statins in the elderly population?. Expert Rev Clin Pharmacol. 11(4), 329-331.
2017
Stavropoulos, K., Imprialos K. P., & Doumas M. (2017).  Abnormal blood pressure dipping in diabetic kidney disease: A black-race nightmare?. J Clin Hypertens (Greenwich). 19(12), 1336-1338.
Doumas, M., Stavropoulos K. V., Boutari C., Imprialos K. P., & Karagiannis A. (2017).  Blood pressure and cardiovascular outcomes: a closer look.. Lancet. 389(10076), 1295-1296.
Papademetriou, V., Nylen E. S., Doumas M., Probstfield J., Mann J. F. E., Gilbert R. E., et al. (2017).  Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study.. Am J Med. 130(12), 1465.e27-1465.e39.
Bress, A. P., King J. B., Kreider K. E., Beddhu S., Simmons D. L., Cheung A. K., et al. (2017).  Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial.. Diabetes Care.
Athyros, V. G., Tziomalos K., Doumas M., Sfikas G., & Karagiannis A. (2017).  The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.. Curr Pharm Des. 23(10), 1477-1483.
Vogiatzakis, N., Tsioufis C., Georgiopoulos G., Thomopoulos C., Dimitriadis K., Kasiakogias A., et al. (2017).  Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension: a meta-analysis.. J Hypertens. 35(9), 1750-1757.
Imprialos, K. P., Stavropoulos K., Doumas M., Karagiannis A., & Athyros V. G. (2017).  The effect of SGLT2 inhibitors on cardiovascular events and renal function.. Expert Rev Clin Pharmacol. 10(11), 1251-1261.
Papademetriou, V., Lovato L., Tsioufis C., Cushman W., Applegate W. B., Mottle A., et al. (2017).  Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study.. Am J Nephrol. 45(2), 136-145.
Narayan, P., Doumas M., Kumar A., Faselis C. J., Myers J. N., Pittaras A., et al. (2017).  Impact of Cardiorespiratory Fitness on Mortality in Black Male Veterans With Resistant Systemic Hypertension.. Am J Cardiol. 120(9), 1568-1571.
Lovic, D., Narayan P., Pittaras A., Faselis C., Doumas M., & Kokkinos P. (2017).  Left ventricular hypertrophy in athletes and hypertensive patients.. J Clin Hypertens (Greenwich). 19(4), 413-417.
Imprialos, K. P., Stavropoulos K., & Doumas M. (2017).  Liraglutide and Renal Outcomes in Type 2 Diabetes.. N Engl J Med. 377(22), 2196.
Faselis, C., Boutari C., Doumas M., Imprialos K., Stavropoulos K., & Kokkinos P. (2017).  Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun.. Curr Pharm Des. 23(10), 1540-1550.
Doumas, M., Stavropoulos K., & Imprialos K. (2017).  Obstructive sleep apnea, hypertension, and fibrin clot properties: a novel pathogenetic link with cardiovascular disease?. J Hypertens. 35(5), 950-952.
Imprialos, K. P., Stavropoulos K., & Doumas M. (2017).  Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.. N Engl J Med. 377(25), 2502.
Raman, V. K., Tsioufis C., Doumas M., & Papademetriou V. (2017).  Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?. Curr Treat Options Cardiovasc Med. 19(5), 39.
Imprialos, K., Faselis C., Boutari C., Stavropoulos K., Athyros V., Karagiannis A., et al. (2017).  SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.. Curr Pharm Des. 23(10), 1510-1521.
Imprialos, K. P., Boutari C., Stavropoulos K., Doumas M., & Karagiannis A. I. (2017).  Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. J Neurol Neurosurg Psychiatry. 88(3), 249-253.
Stavropoulos, K., Imprialos K. P., & Doumas M. (2017).  Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look at Additional Parameters.. JAMA Intern Med. 177(9), 1393.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές